Clinical Research Directory
Browse clinical research sites, groups, and studies.
Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
This study aims to validate the efficacy and safety of GP/GEMOX combined with PD-1/L1 inhibitors and TKI agents in patients with advanced cholangiocarcinoma through a multicenter, retrospective study to guide clinical practice.
Official title: Chemotherapy Combined with Immunotherapy and Targeted Therapy in Advanced Intrahepatic Cholangiocarcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2024-09-01
Completion Date
2025-05-31
Last Updated
2025-02-06
Healthy Volunteers
No
Conditions
Interventions
Gemcitabine combined with cisplatin or oxaliplatin
Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)
Locations (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China